{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:37:37Z","timestamp":1781649457513,"version":"3.54.5"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and are increasingly associated with cardiovascular toxicities, including myocarditis and accelerated atherosclerosis. While ICI myocarditis has received substantial attention, thrombotic complications remain underrecognized and may be difficult to distinguish from immune-mediated cardiac inflammation and cancer-related hypercoagulable state. We present a case of non-bacterial thrombotic endocarditis (NBTE) and myocardial microthrombi mimicking ICI myocarditis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 76-year-old woman with metastatic adenosquamous lung carcinoma presented with progressive dyspnoea 3 weeks after initiating pembrolizumab. Pulmonary arterial and coronary imaging were unremarkable, but cardiac magnetic resonance imaging (MRI) showed late gadolinium enhancement (LGE) and myocardial oedema suggestive of ICI myocarditis. Chest computed tomography revealed inflammatory lung changes, and empirical corticosteroids were initiated with initial clinical improvement. One week later, brain MRI showed multifocal infarcts, and Doppler ultrasound identified bilateral lower extremity deep vein thromboses. Transoesophageal echocardiography showed thickened mitral and aortic valves with moderate regurgitation. Non-bacterial thrombotic endocarditis with embolic phenomena was suspected. Anticoagulation was escalated from apixaban to therapeutic enoxaparin, followed by warfarin. Despite initial stabilization, the patient died 2 months later. Post-mortem examination revealed fibrin-rich valvular vegetations consistent with NBTE, widespread intramyocardial thrombi, and no histopathologic evidence of myocarditis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case underscores how microthrombotic complications of ICI therapy may closely mimic myocarditis on imaging. Nonspecific cardiac MRI findings, such as LGE and T2 signal elevation, can result from thrombotic or ischaemic injury alike. Histopathologic confirmation may be required for accurate diagnosis, as misclassification can lead to suboptimal treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytag305","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T11:39:04Z","timestamp":1778326744000},"source":"Crossref","is-referenced-by-count":1,"title":["Non-bacterial thrombotic endocarditis and intraventricular small-vessel thromboembolic occlusion mimicking immune checkpoint inhibitor myocarditis in a patient treated with pembrolizumab: a case report"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4019-6410","authenticated-orcid":false,"given":"Agata","family":"Sularz","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A","family":"Holthe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B","family":"Geske","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3093-3744","authenticated-orcid":false,"given":"Melanie C","family":"Bois","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]},{"name":"Department of Pathology, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4972-5160","authenticated-orcid":false,"given":"John P","family":"Bois","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]},{"name":"Department of Radiology, Mayo Clinic , 200 First Street SW, Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2026052019393906400_ytag305-B1","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur Heart J"},{"key":"2026052019393906400_ytag305-B2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor\u2013induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026052019393906400_ytag305-B3","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.thromres.2022.01.004","article-title":"Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies","volume":"213","author":"Moik","year":"2022","journal-title":"Thromb Res"},{"key":"2026052019393906400_ytag305-B4","first-page":"1669","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood J Am Soc Hematol"},{"key":"2026052019393906400_ytag305-B5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026052019393906400_ytag305-B6","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/eurheartj\/eht100","article-title":"Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage","volume":"34","author":"Robbers","year":"2013","journal-title":"Eur Heart J"},{"key":"2026052019393906400_ytag305-B7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1148\/rg.291085052","article-title":"A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging","volume":"29","author":"Cummings","year":"2009","journal-title":"Radiographics"},{"key":"2026052019393906400_ytag305-B8","doi-asserted-by":"crossref","first-page":"ytac318","DOI":"10.1093\/ehjcr\/ytac318","article-title":"Evaluations of coronary microvascular dysfunction in a patient with thrombotic microangiopathy and cardiac troponin elevation: a case report","volume":"7","author":"Otsuka","year":"2023","journal-title":"Eur Heart J Case Rep"},{"key":"2026052019393906400_ytag305-B9","first-page":"691","article-title":"The utility of troponin measurement to detect myocardial infarction: review of the current findings","volume":"6","author":"Daubert","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"2026052019393906400_ytag305-B10","doi-asserted-by":"crossref","first-page":"20140470","DOI":"10.1259\/bjr.20140470","article-title":"Cardiac MR assessment of microvascular obstruction","volume":"88","author":"Abbas","year":"2015","journal-title":"Br J Radiol"},{"key":"2026052019393906400_ytag305-B11","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026052019393906400_ytag305-B12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00262-024-03850-y","article-title":"Interdependence of coagulation with immunotherapy and BRAF\/MEK inhibitor therapy: results from a prospective study","volume":"74","author":"Beckmann","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026052019393906400_ytag305-B13","first-page":"965","article-title":"Early change in C-reactive protein and venous thromboembolism in patients treated with immune checkpoint inhibitors","volume":"6","author":"Moik","year":"2024","journal-title":"Cardio Oncology"},{"key":"2026052019393906400_ytag305-B14","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest"},{"key":"2026052019393906400_ytag305-B15","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.amjmed.2025.05.025","article-title":"Assessing the efficacy of direct oral anticoagulants in nonbacterial thrombotic endocarditis patients","volume":"138","author":"Tran","year":"2025","journal-title":"Am J Med"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytag305\/68274866\/ytag305.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/10\/5\/ytag305\/68274866\/ytag305.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/10\/5\/ytag305\/68274866\/ytag305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:39:47Z","timestamp":1779320387000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytag305\/8676667"}},"subtitle":[],"editor":[{"given":"Golnaz","family":"Houshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Sarandeep Kaur","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Alessandro","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Ugur","family":"Canpolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytag305","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,30]]},"article-number":"ytag305"}}